I write these macro updates infrequently. I try to do so when I have something significant to say that’s different from the dominant narrative. Conventional wisdom in the markets is correct more often than not. But when I find myself annoyed at the obvious falsehoods in the financial reporting and on Fin-X on a daily … Read more
Overview: Today, we got the August Consumer Price Index (CPI) report which showed an overall increase of 2.9% for the last year and up 0.4% for the month (annualizes to 4.9%). The annual number is up 0.2% from July and 0.1% above expectations. The monthly is up 0.2% and 0.1% above expectations. The Core CPI … Read more
Judge Amit Mehta, an Obama appointee, determined Google was abusing an illegal monopoly. The law says he’s supposed to end the monopoly and eliminate the profits from it. Instead, he left it in place and Google is still sending Apple tens of billions of dollars a year. Revolution Wind had its wind power project stopped … Read more
MannKind has announced the tender date for scPharma is October 6th, 2025. If you want to own the contingent value right (CVR), you should keep your shares and tender them in the offer. If you don’t want to own the CVR, then you should sell your shares prior to October 6th. The documents filed … Read more
MannKind is acquiring DKI portfolio position scPharmaceuticals ($SCPH) for $5.35/share in cash and a contingent value right worth up to $1.00. It’s the second medical device acquisition from the DKI portfolio in the past two years and the third acquisition premium in four years. Steel prices fall as US suppliers increase capacity. Just a couple … Read more
Hi All, Good news. As promised, we’ve implemented a new meeting feature. I’ve opened up two 30 minute slots every Monday starting after the coming holiday weekend. These are private Zoom meetings to discuss whatever is on your mind. Flying V’s Kashif has worked some cool magic here so if you’re a DKI Premium Subscriber … Read more
At DKI, we’ve been making an effort to be more transparent in how we make investment decisions and to provide more educational content. There are several interesting lessons which can be extracted from the recent scPharma takeover announcement. Before we dive in, I want to be clear that while a likely acquisition was a key … Read more
